Literature DB >> 1310697

Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry.

J H Chiu1, H L Kao, L H Wu, H M Chang, W Y Lui.   

Abstract

To investigate the change of DNA content and the effect of synthetic phase (S-phase) fraction on hepatocytes and hepatomas, DNA content and S-phase fraction were measured by flow cytometry in human livers and hepatoma tissues. The ploidy status of nontumor parts of resected hepatoma, fetal liver, and focal nodular hyperplasia were diploid, similar to that of the normal liver. Three patterns of DNA ploidy in human hepatoma cells were newly classified, namely, pattern I, diploid tumors; pattern II, aneuploid tumors with single G0/G1 peak; and pattern III, aneuploid tumors with more than one G0/G1 peaks. Among the 130 resectable hepatomas measured for DNA ploidy status, 84 (64.6%) were pattern I, 20 (15.4%) pattern II, and 26 (20%) pattern III. Multivariate analyses for those 130 patients who underwent hepatic resection showed that, in addition to tumor size, DNA ploidy was another prognostic factor in predicting overall survival and disease-free survival. Patients with small tumors (less than 5 cm) had a significantly higher overall survival rate than those with large tumor (greater than 5 cm). Patients with pattern III hepatomas had a significantly lower overall survival rate and a higher recurrent rate than did those with pattern I or pattern II tumors. The S-phase fraction was a significant predictor of overall survival rate in patients with pattern II, but not with pattern I, tumors. We conclude that DNA flow-cytometric measurements of ploidy and S-phase fraction are potential important prognostic predictors in patients with resectable hepatomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310697      PMCID: PMC442885          DOI: 10.1172/JCI115618

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Primary liver-cell carcinoma with a protracted clinical course. Report of a case.

Authors:  D D HUNT
Journal:  JAMA       Date:  1963-04-13       Impact factor: 56.272

Review 2.  Flow cytometry using paraffin-embedded tissue: five years on.

Authors:  D W Hedley
Journal:  Cytometry       Date:  1989-05

3.  Effect of section thickness on quality of flow cytometric DNA content determinations in paraffin-embedded tissues.

Authors:  R A Stephenson; H Gay; W R Fair; M R Melamed
Journal:  Cytometry       Date:  1986-01

4.  DNA analysis of hepatocellular carcinoma and clinicopathologic implications.

Authors:  T Ezaki; T Kanematsu; T Okamura; T Sonoda; K Sugimachi
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

5.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

Authors:  G M Clark; L G Dressler; M A Owens; G Pounds; T Oldaker; W L McGuire
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

6.  The polyploidizing growth pattern of normal rat liver is replaced by divisional, diploid growth in hepatocellular nodules and carcinomas.

Authors:  G Saeter; P E Schwarze; J M Nesland; N Juul; E O Pettersen; P O Seglen
Journal:  Carcinogenesis       Date:  1988-06       Impact factor: 4.944

7.  Rapid DNA evaluation in clinical diagnosis.

Authors:  G L Wied; P H Bartels; H E Dytch; M Bibbo
Journal:  Acta Cytol       Date:  1983 Jan-Feb       Impact factor: 2.319

8.  Changes in ploidy distributions in human liver carcinogenesis.

Authors:  G Saeter; C Z Lee; P E Schwarze; S Ous; D S Chen; J L Sung; P O Seglen
Journal:  J Natl Cancer Inst       Date:  1988-11-16       Impact factor: 13.506

9.  DNA content of liver cell nuclei of N-2-fluorenylacetamide-induced altered foci and neoplasms in rats and human hyperplastic foci.

Authors:  H Mori; T Tanaka; S Sugie; M Takahashi; G M Williams
Journal:  J Natl Cancer Inst       Date:  1982-12       Impact factor: 13.506

10.  Emergence of a population of small, diploid hepatocytes during hepatocarcinogenesis.

Authors:  P E Schwarze; E O Pettersen; M C Shoaib; P O Seglen
Journal:  Carcinogenesis       Date:  1984-10       Impact factor: 4.944

View more
  7 in total

1.  Cellular DNA content and histopathological analysis in hepatocellular carcinoma with multiple nodules.

Authors:  N Ichikawa; J Fujimoto; E Okamoto; N Yamanaka; T Nishigami
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 3.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

4.  Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer.

Authors:  Chew-Wun Wu; Chin-Wen Chi; Tze-Sing Huang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

5.  Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Authors:  James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

6.  Heterogeneity of DNA content in multiple synchronous hepatocellular carcinomas.

Authors:  A M Hui; S Kawasaki; H Imamura; S Miyagawa; K Ishii; T Katsuyama; M Makuuchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study.

Authors:  Mohannad Dugum; Ibrahim Hanouneh; Thomas McIntyre; Rish Pai; Federico Aucejo; Bijan Eghtesad; Nizar Zein
Journal:  Mol Clin Oncol       Date:  2016-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.